The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020
Open accessAbstract
Importance: Case-based surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection likely underestimates the true prevalence of infections. Large-scale seroprevalence surveys can better estimate infection across many geographic regions. Objective: To estimate the prevalence of persons with SARS-CoV-2 antibodies using residual sera from commercial laboratories across the US and assess changes over time. Design, Setting, and Participants: This repeated, cross-sectional study conducted across all 50 states, the District of Columbia, and Puerto Rico used a convenience sample of residual serum specimens provided by persons of all ages that were originally submitted for routine screening or clinical management from 2 private clinical commercial laboratories. Samples were obtained during 4 collection periods: July 27 to August 13, August 10 to August 27, August 24 to September 10, and September 7 to September 24, 2020. Exposures: Infection with SARS-CoV-2. Main Outcomes and Measures: The proportion of persons previously infected with SARS-CoV-2 as measured by the presence of antibodies to SARS-CoV-2 by 1 of 3 chemiluminescent immunoassays. Iterative poststratification was used to adjust seroprevalence estimates to the demographic profile and urbanicity of each jurisdiction. Seroprevalence was estimated by jurisdiction, sex, age group (0-17, 18-49, 50-64, and ≥65 years), and metropolitan/nonmetropolitan status. Results: Of 177 919 serum samples tested, 103 771 (58.3%) were from women, 26 716 (15.0%) from persons 17 years or younger, 47 513 (26.7%) from persons 65 years or older, and 26 290 (14.8%) from individuals living in nonmetropolitan areas. Jurisdiction-level seroprevalence over 4 collection periods ranged from less than 1% to 23%. In 42 of 49 jurisdictions with sufficient samples to estimate seroprevalence across all periods, fewer than 10% of people had detectable SARS-CoV-2 antibodies. Seroprevalence estimates varied between sexes, across age groups, and between metropolitan/nonmetropolitan areas. Changes from period 1 to 4 were less than 7 percentage points in all jurisdictions and varied across sites. Conclusions and Relevance: This cross-sectional study found that as of September 2020, most persons in the US did not have serologic evidence of previous SARS-CoV-2 infection, although prevalence varied widely by jurisdiction. Biweekly nationwide testing of commercial clinical laboratory sera can play an important role in helping track the spread of SARS-CoV-2 in the US.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Bootstrap methods: another look at the jackknife
Efron, B. (1979) · The Annals of Statistics · doi:10.1214/aos/1176344552 · Cited by 17,602
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
COVID-19 and the impact of social determinants of health
Abrams, E. M., & Szefler, S. J. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30234-4 · Cited by 711
COVID-19 antibody seroprevalence in santa clara county, california
Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., Weissberg, Z., Saavedra-Walker, R., Tedrow, J., Bogan, A., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab010 · Cited by 669
Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020
Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C.-F., Gibbons, A., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4130 · Cited by 647
Self-citationThe many faces of the anti-COVID immune response
Vardhana, S. A., & Wolchok, J. D. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200678 · Cited by 509
Electronic Code of Federal Regulations
(2018) · Cited by 491
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S., Bowen, V., Chow, N., Curns, A., Gierke, R., Hall, A., Hughes, M., Pilishvili, T., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e4 · Cited by 460
Self-citationSood, N., Simon, P., Ebner, P., Eichner, D., Reynolds, J., Bendavid, E., & Bhattacharya, J. (2020) · JAMA · doi:10.1001/jama.2020.8279 · Cited by 406
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Ainsworth, M., Andersson, M., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30634-4 · Cited by 351
SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
Ward, H., Atchison, C., Whitaker, M., Ainslie, K. E. C., Elliott, J., Okell, L., Redd, R., Ashby, D., Donnelly, C. A., Barclay, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21237-w · Cited by 337
Natural History of Asymptomatic SARS-CoV-2 Infection
Sakurai, A., Sasaki, T., Kato, S., Hayashi, M., Tsuzuki, S.-I., Ishihara, T., Iwata, M., Morise, Z., & Doi, Y. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2013020 · Cited by 274
Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265
Anand, S., Montez-Rath, M., Han, J., Bozeman, J., Kerschmann, R., Beyer, P., Parsonnet, J., & Chertow, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32009-2 · Cited by 265
Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
Rosenberg, E. S., Tesoriero, J. M., Rosenthal, E. M., Chung, R., Barranco, M. A., Styer, L. M., Parker, M. M., John Leung, S.-Y., Morne, J. E., Greene, D., et al. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.06.004 · Cited by 262
Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area
Moscola, J., Sembajwe, G., Jarrett, M., Farber, B., Chang, T., McGinn, T., Davidson, K. W., & Northwell Health COVID-19 Research Consortium (2020) · JAMA · doi:10.1001/jama.2020.14765 · Cited by 260
Practical Considerations in Raking Survey Data
Battaglia, M. P., Hoaglin, D. C., & Frankel, M. R. (2009) · Survey Practice · doi:10.29115/sp-2009-0019 · Cited by 231
COVID-19 and the Path to Immunity
Stephens, D. S., & McElrath, M. J. (2020) · JAMA · doi:10.1001/jama.2020.16656 · Cited by 217
Self, W. H., Tenforde, M. W., Stubblefield, W. B., Feldstein, L. R., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Prekker, M. E., Brown, S. M., Peltan, I. D., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6935e2 · Cited by 202
Self-citationTechnical Guidelines for COVID-19 Laboratory Testing
Center for Disease Control and Prevention, C. (2020) · China CDC Weekly · doi:10.46234/ccdcw2020.085 · Cited by 197
Payne, D. C., Smith-Jeffcoat, S. E., Nowak, G., Chukwuma, U., Geibe, J. R., Hawkins, R. J., Johnson, J. A., Thornburg, N. J., Schiffer, J., Weiner, Z., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6923e4 · Cited by 195
Self-citationEvidence for Limited Early Spread of COVID-19 Within the United States, January–February 2020
CDC COVID-19 Response Team, Jorden, M. A., Rudman, S. L., Villarino, E., Hoferka, S., Patel, M. T., Bemis, K., Simmons, C. R., Jespersen, M., Iberg Johnson, J., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6922e1 · Cited by 168
Ward, H., Atchison, C. J., Whitaker, M. D., et al. (2020) · medRxiv · doi:10.1101/2020.08.12.20173690v2 · Cited by 155
Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review
Cheng, M. P., Yansouni, C. P., Basta, N. E., Desjardins, M., Kanjilal, S., Paquette, K., Caya, C., Semret, M., Quach, C., Libman, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2854 · Cited by 149
Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee
Patel, M. M., Thornburg, N. J., Stubblefield, W. B., Talbot, H. K., Coughlin, M. M., Feldstein, L. R., & Self, W. H. (2020) · JAMA · doi:10.1001/jama.2020.18796 · Cited by 128
Self-citationLewis, N. M., Friedrichs, M., Wagstaff, S., Sage, K., LaCross, N. C., Bui, D. P., McCaffrey, K., Barbeau, B., George, A., Rosé, C. P., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6938a4 · Cited by 124
Okoro, C. A., Zhao, G., Fox, J. B., Eke, P. I., Greenlund, K. J., & Town, M. (2017) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6607a1 · Cited by 95
The COVID-19 Serology Studies Workshop: Recommendations and Challenges
Lerner, A. M., Eisinger, R. W., Lowy, D. R., Petersen, L. R., Humes, R., Hepburn, M. J., & Cassetti, M. C. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.012 · Cited by 71
Self-citationYousaf, A. R., Duca, L. M., Chu, V. T., Reses, H. E., Fajans, M., Rabold, E. M., Laws, R. L., Gharpure, R. V., Matanock, A. M., Wadhwa, A., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1072 · Cited by 54
Self-citationDodd, R. Y., Xu, M. J., & Stramer, S. L. (2020) · JAMA · doi:10.1001/jama.2020.18598 · Cited by 36
Prince, H. E., Givens, T. S., Lapé-Nixon, M., Clarke, N. J., Schwab, D. A., Batterman, H. J., Jones, R. S., Meyer, W. A., Kapoor, H., Rowland, C. M., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01742-20 · Cited by 33
Self-citation
Cited by
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B. (2021) · Science · doi:10.1126/science.abe6959 · Cited by 775
Jones, J. M., Stone, M., Sulaeman, H., Fink, R. V., Dave, H., Levy, M. E., Di Germanio, C., Green, V., Notari, E., Saa, P., et al. (2021) · JAMA · doi:10.1001/jama.2021.15161 · Cited by 201
Self-citationBurden and characteristics of COVID-19 in the United States during 2020
Pei, S., Yamana, T. K., Kandula, S., Galanti, M., & Shaman, J. (2021) · Nature · doi:10.1038/s41586-021-03914-4 · Cited by 190
Mulenga, L. B., Hines, J. Z., Fwoloshi, S., Chirwa, L., Siwingwa, M., Yingst, S., Wolkon, A., Barradas, D. T., Favaloro, J., Zulu, J. E., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00053-x · Cited by 149
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
Adetifa, I. M. O., Uyoga, S., Gitonga, J. N., Mugo, D., Otiende, M., Nyagwange, J., Karanja, H. K., Tuju, J., Wanjiku, P., Aman, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24062-3 · Cited by 67
Metadata
- Authors
- Bajema, K. L., Wiegand, R. E., Cuffe, K., Patel, S. V., Iachan, R., Lim, T., Lee, A., Moyse, D., Havers, F. P., Harding, L., Fry, A. M., Hall, A. J., Martin, K., Biel, M., Deng, Y., Meyer, W. A., Mathur, M., Kyle, T., Gundlapalli, A. V., Thornburg, N. J., Petersen, L. R., & Edens, C.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2021-04-01
- Volume
- 181
- Issue
- 4
- Pages
- 450
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W3108096807
- Cited by
- 276
- References
- 41
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.